Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3,761 INR | -0.08% | -0.51% | -3.68% |
Apr. 12 | Indian Equities Close Lower on Friday As Hopes for US Rate Cute in June Fade | MT |
Apr. 10 | Indian Equities End Higher on Wednesday, Lifted Mainly by Metal Stocks | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 64.44 and 48.83 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.68% | 11.94B | B | ||
+28.79% | 676B | C+ | ||
+24.81% | 554B | B | ||
-7.64% | 349B | C+ | ||
+15.00% | 318B | B- | ||
+5.99% | 291B | C+ | ||
+2.47% | 210B | B+ | ||
-0.02% | 204B | B- | ||
-9.98% | 194B | A+ | ||
-11.71% | 144B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DIVISLAB Stock
- Ratings Divi's Laboratories Limited